Mountain Pacific Investment Advisers LLC Lowers Stake in Danaher Corporation (NYSE:DHR)

Mountain Pacific Investment Advisers LLC reduced its position in Danaher Corporation (NYSE:DHR - Free Report) by 0.9% in the 1st quarter, according to its most recent filing with the SEC. The firm owned 208,315 shares of the conglomerate's stock after selling 1,974 shares during the period. Danaher accounts for approximately 3.2% of Mountain Pacific Investment Advisers LLC's investment portfolio, making the stock its 9th largest holding. Mountain Pacific Investment Advisers LLC's holdings in Danaher were worth $42,705,000 at the end of the most recent reporting period.

A number of other institutional investors have also made changes to their positions in the stock. Highline Wealth Partners LLC grew its stake in shares of Danaher by 0.8% during the first quarter. Highline Wealth Partners LLC now owns 7,385 shares of the conglomerate's stock worth $1,514,000 after purchasing an additional 59 shares during the period. Sagespring Wealth Partners LLC grew its stake in shares of Danaher by 14.0% during the first quarter. Sagespring Wealth Partners LLC now owns 4,535 shares of the conglomerate's stock worth $930,000 after purchasing an additional 556 shares during the period. Great Lakes Retirement Inc. grew its stake in Danaher by 7.3% in the first quarter. Great Lakes Retirement Inc. now owns 39,687 shares of the conglomerate's stock valued at $8,136,000 after acquiring an additional 2,685 shares during the period. Cypress Advisory Group LLC grew its stake in Danaher by 87.2% in the first quarter. Cypress Advisory Group LLC now owns 2,995 shares of the conglomerate's stock valued at $614,000 after acquiring an additional 1,395 shares during the period. Finally, Adero Partners LLC grew its stake in Danaher by 11.2% in the first quarter. Adero Partners LLC now owns 1,953 shares of the conglomerate's stock valued at $400,000 after acquiring an additional 197 shares during the period. 79.05% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of research firms have issued reports on DHR. Evercore ISI decreased their target price on Danaher from $240.00 to $230.00 and set an "outperform" rating for the company in a research note on Tuesday, April 22nd. Wells Fargo & Company reduced their price objective on Danaher from $240.00 to $210.00 and set an "equal weight" rating for the company in a research report on Wednesday, April 23rd. UBS Group reduced their price objective on Danaher from $275.00 to $240.00 and set a "buy" rating for the company in a research report on Wednesday, April 23rd. Leerink Partners upped their price objective on Danaher from $225.00 to $230.00 and gave the stock an "outperform" rating in a research report on Wednesday, April 23rd. Finally, JPMorgan Chase & Co. reduced their price objective on Danaher from $280.00 to $260.00 and set an "overweight" rating for the company in a research report on Tuesday, April 22nd. Five equities research analysts have rated the stock with a hold rating and sixteen have assigned a buy rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and a consensus target price of $248.17.

Danaher Trading Down 0.7%

Shares of DHR traded down $1.39 during mid-day trading on Thursday, reaching $194.36. 3,236,239 shares of the company were exchanged, compared to its average volume of 3,488,121. Danaher Corporation has a 52 week low of $171.00 and a 52 week high of $281.70. The company has a debt-to-equity ratio of 0.31, a quick ratio of 1.05 and a current ratio of 1.43. The stock has a market capitalization of $139.10 billion, a PE ratio of 37.74, a PEG ratio of 2.75 and a beta of 0.77. The business has a 50 day simple moving average of $193.46 and a two-hundred day simple moving average of $210.32.

Danaher (NYSE:DHR - Get Free Report) last issued its earnings results on Tuesday, April 22nd. The conglomerate reported $1.88 earnings per share for the quarter, topping analysts' consensus estimates of $1.62 by $0.26. Danaher had a return on equity of 10.80% and a net margin of 15.81%. The business had revenue of $5.74 billion during the quarter, compared to the consensus estimate of $5.58 billion. On average, analysts predict that Danaher Corporation will post 7.63 earnings per share for the current fiscal year.

Danaher Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Friday, July 25th. Shareholders of record on Friday, June 27th will be paid a $0.32 dividend. This represents a $1.28 dividend on an annualized basis and a yield of 0.66%. Danaher's dividend payout ratio (DPR) is presently 24.85%.

Insider Activity at Danaher

In related news, Chairman Steven M. Rales sold 1,250,000 shares of Danaher stock in a transaction that occurred on Monday, May 12th. The stock was sold at an average price of $196.74, for a total transaction of $245,925,000.00. Following the transaction, the chairman now owns 3,105,808 shares of the company's stock, valued at $611,036,665.92. The trade was a 28.70% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, EVP Christopher Paul Riley sold 15,805 shares of Danaher stock in a transaction on Wednesday, April 30th. The stock was sold at an average price of $198.00, for a total value of $3,129,390.00. Following the sale, the executive vice president now owns 15,179 shares in the company, valued at $3,005,442. This trade represents a 51.01% decrease in their ownership of the stock. The disclosure for this sale can be found here. 11.10% of the stock is owned by insiders.

About Danaher

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.